Hangzhou Huangsen Biotechnology Co., Ltd.

The purpose of this study was to study the pharmacokinetic characteristics of a single fasting oral dose of mesalazine enteric-coated tablets (0.5 g) produced by Hangzhou Huangsen Biotechnology Co., Ltd. and Zhejiang Jingxin Pharmaceutical Co., Ltd.; using mesalazine enteric-coated tablets (Salfo®, 0.5 g) produced by Losan Pharma GmbH as the reference preparation, the pharmacokinetic parameters Cmax and AUC0-t of the two preparations were compared, and the bioequivalence of the two preparations in humans was evaluated.

This study aimed to investigate the pharmacokinetic characteristics of single fasting and postprandial oral administration of mesalazine enteric-coated tablets (0.5 g) produced by Hangzhou Huangsen Biotechnology Co., Ltd. and Zhejiang Jingxin Pharmaceutical Co., Ltd.; using mesalazine enteric-coated tablets (Salfo®, 0.5 g) produced by Losan Pharma GmbH as the reference preparation, the pharmacokinetic parameters Cmax and AUC0-t of the two preparations were compared, and the bioequivalence of the two preparations in humans was evaluated.

This study aimed to investigate the pharmacokinetic characteristics of single fasting and postprandial oral administration of vonoprazan fumarate tablets (20 mg) developed by Hangzhou Huangsen Biotechnology Co., Ltd. and produced by Zhejiang Jingxin Pharmaceutical Co., Ltd.; using vonoprazan fumarate tablets (Walker®, 20 mg) produced by Takeda Pharmaceutical Company Limited as the reference preparation, the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations were compared, and the bioequivalence of the two preparations in humans was evaluated.